Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LSS | P48449 | 9/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 4/20 | 0.38 |
| ▸ | CCR6 | P51684 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6018429 | 1.00 | LSS (0.59) | LSSLMNAL3MBTL1MAPTSMN1; SMN2 | |
| SCHEMBL6018261 | 0.94 | LSS (0.64) | LSSLMNAL3MBTL1MAPTSMN1; SMN2 | |
| SCHEMBL6018263 | 0.94 | LSS (0.64) | LSSLMNAL3MBTL1MAPTSMN1; SMN2 | |
| SCHEMBL6018340 | 0.90 | LSS (0.67) | LSSLMNAL3MBTL1MAPTSMN1; SMN2 | |
| SCHEMBL6018344 | 0.90 | LSS (0.67) | LSSLMNAL3MBTL1MAPTSMN1; SMN2 | |
| SCHEMBL6019063 | 0.89 | LSS (0.69) | LSSLMNAL3MBTL1MAPTSMN1; SMN2 | |
| SCHEMBL6019068 | 0.89 | LSS (0.69) | LSSLMNAL3MBTL1MAPTSMN1; SMN2 | |
| SCHEMBL6018466 | 0.88 | LSS (0.55) | LSSLMNAL3MBTL1MAPTSMN1; SMN2 | |
| SCHEMBL6018799 | 0.88 | LSS (0.55) | LSSLMNAL3MBTL1MAPTSMN1; SMN2 | |
| SCHEMBL6018798 | 0.88 | LSS (0.55) | LSSLMNAL3MBTL1MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1456171-B1 | SUBSTITUTED CYCLOHEXANE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2006-12-20 | — | — | EP | disclosed |
| US-20050272774-A1 | Substituted cyclohexane derivatives | ACKERMANN JEAN | 2005-12-08 | — | — | US | disclosed |
| US-6953806-B2 | Substituted cyclohexane derivatives | HOFFMANN-LA ROCHE INC. (US) | 2005-10-11 | — | — | US | disclosed |
| EP-1456171-A1 | SUBSTITUTED CYCLOHEXANE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2004-09-15 | — | — | EP | disclosed |
| US-20030199550-A1 | Substituted cyclohexane derivatives | F.HOFFMANN-LA ROCHE AG (CH) | 2003-10-23 | — | — | US | disclosed |
| WO-2003053919-A1 | SUBSTITUTED CYCLOHEXANE DERIVATIVES | F. HOFFMANN-LA-ROCHE AG (CH) | 2003-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050272774-A1 | Substituted cyclohexane derivatives | LSS, CYP51A1, CYP8B1 | LSS 1/4885LMNA 280/4885L3MBTL1 1311/4885 |
| US-20030199550-A1 | Substituted cyclohexane derivatives | CYP51A1, LSS, CYP46A1 | LSS 2/4885LMNA 485/4885L3MBTL1 1655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.